Joshua Meier

Sean McClain, Founder and CEO of Absci, and Joshua Meier, Lead AI Scientist at Absci, share insights on how AI is revolutionizing drug discovery. They discuss the transition from traditional methods to AI-driven techniques, emphasizing the potential of digital twins and mRNA technology. The duo explores how AI analyzes biological data for personalized medicine and enhances clinical trials. With promises of more efficient drug development, their vision showcases a future where AI solutions lead to innovative healthcare transformations.